In Vitro Activity of New β-Lactam–β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019

Novel β-lactam–β-lactamase inhibitor combinations (BLBLIs) are in clinical development for the treatment of infections caused by carbapenem-resistant and difficult-to-treat resistant (DTR) (defined as resistance to all tested β-lactams and fluoroquinolones) Gram-negative bacilli. This study evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yan, Han, Renru, Jiang, Bo, Ding, Li, Yang, Fengzhen, Zheng, Beijia, Yang, Yang, Wu, Shi, Yin, Dandan, Zhu, Demei, Hu, Fupin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431184/
https://www.ncbi.nlm.nih.gov/pubmed/35862963
http://dx.doi.org/10.1128/spectrum.01854-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431184/
https://www.ncbi.nlm.nih.gov/pubmed/35862963
http://dx.doi.org/10.1128/spectrum.01854-22

Ejemplares similares